Half-year report · Q2
4896.TEDINET S100U7NL
Period2024-01-01 → 2024-06-30
Filed2024-08-14
StandardJapan GAAP
ConsolidatedNo
Data checks11 of 11 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.0bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.0bn | 2023-01-01 → 2023-06-30 | Standalone | Net sales |
| Operating income | −¥423m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Operating income | ¥651m | 2023-01-01 → 2023-06-30 | Standalone | Operating income |
| Ordinary income | −¥423m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥344m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥651m | 2023-01-01 → 2023-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥425m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥615m | 2023-01-01 → 2023-06-30 | Standalone | Income before income taxes |
| Net income | −¥427m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Net income | ¥260m | 2023-01-01 → 2023-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | ¥515m | 2023-01-01 → 2023-06-30 | Standalone | Profit loss |
| Total assets | ¥2.8bn | at 2024-06-30 | Standalone | Assets |
| Total assets | ¥3.3bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥2.2bn | at 2023-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111m | at 2024-06-30 | Standalone | Liabilities |
| Total liabilities | ¥209m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.7bn | at 2024-06-30 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2023-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.7bn | at 2024-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.3bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.7bn | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-12-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥562m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥454m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥849m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥9m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥11m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10m | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥90,000 | 2023-01-01 → 2023-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-36.75 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.42 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.11 | 2023-01-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥23.07 | 2023-01-01 → 2023-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| Equity ratio | 96.0% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.7% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.2% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 11,604,600 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,604,600 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,879 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 328
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in investment activities | CurrentYTDDuration_NonConsolidatedMember | -9306000 | JPY |
| Payments for issuance of share acquisition rights fin cf | Prior1YTDDuration_NonConsolidatedMember | -90000 | JPY |
| Payments for issuance of share acquisition rights fin cf | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration_NonConsolidatedMember | -90000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration_NonConsolidatedMember | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration_NonConsolidatedMember | 838656000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration_NonConsolidatedMember | -571752000 | JPY |
| Cash and cash equivalents | Prior2YearInstant_NonConsolidatedMember | 1336847000 | JPY |
| Cash and cash equivalents | Prior1YearInstant_NonConsolidatedMember | 3266408000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant_NonConsolidatedMember | 2175504000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant_NonConsolidatedMember | 2694656000 | JPY |
| Research and development expenses sga | Prior1YTDDuration_NonConsolidatedMember | 106710000 | JPY |
| Research and development expenses sga | CurrentYTDDuration_NonConsolidatedMember | 236790000 | JPY |
| Directors compensations sga | Prior1YTDDuration_NonConsolidatedMember | 36200000 | JPY |
| Directors compensations sga | CurrentYTDDuration_NonConsolidatedMember | 51600000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration_NonConsolidatedMember | 27175000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration_NonConsolidatedMember | 26856000 | JPY |
| Commission fee sga | Prior1YTDDuration_NonConsolidatedMember | 24257000 | JPY |
| Commission fee sga | CurrentYTDDuration_NonConsolidatedMember | 36478000 | JPY |
| Rent expenses sga | Prior1YTDDuration_NonConsolidatedMember | 13900000 | JPY |
| Rent expenses sga | CurrentYTDDuration_NonConsolidatedMember | 17081000 | JPY |
| Taxes and dues sga | Prior1YTDDuration_NonConsolidatedMember | 24094000 | JPY |
| Taxes and dues sga | CurrentYTDDuration_NonConsolidatedMember | 468000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-08-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第８期中(自 2024年１月１日 至 2024年６月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ケイファーマ | |
| Company name in english cover page | FilingDateInstant | K Pharma,Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 福島 弘明 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区六本木七丁目７番７号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6629-3380 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務取締役CFO 松本 真佐人 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区六本木七丁目７番７号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6629-3380 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務取締役CFO 松本 真佐人 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E38985 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 48960 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ケイファーマ | |
| Filer name in english | FilingDateInstant | K Pharma, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 11 of 11 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |